Acumen Pharmaceuticals, Inc. (ABOS) Tops Q3 EPS by 2c

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) reported Q3 EPS of ($0.24), $0.02 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Acumen Pharmaceuticals, Inc. (ABOS) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Morgan Stanley Starts Adani Enterprises Ltd. (ADE:IN) at Overweight
• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold